Abdurashid Mussayev
Research Subjects
Abdurashid Mussayev has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Aidyn Kuanyshbek
Department of Anesthesiology, National Research Cardiac Surgery Center, Astana 020000, Kazakhstan
1 shared publication - Aigerim Kunakbayeva
Department of Adult Cardiac Surgery, National Research Cardiac Surgery Center, Astana 020000, Kazakhstan
1 shared publication - Aigerim Sadykova
National Research Center for Cardiac Surgery, Astana 010000, Kazakhstan
1 shared publication - Linar Faizov
National Research Cardiac Surgery Center
1 shared publication - Makhabbat Bekbossynova
“University Medical Center” Corporate Fund, Heart Center, Nazarbayev University, Astana, Republic of Kazakhstan
1 shared publication - Rymbay Kaliyev
National Research Cardiac Surgery Center
1 shared publication
Latest Publications
- Open Access
- 20 January 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (3) , 859
Prophylactic Awake Peripheral V-A ECMO during TAVR
Introduction: TAVR remains a complex procedure that may result in serious intraprocedural complications. In many of these circumstances, venoarterial extracorporeal membrane oxygenation (V-A ECMO) helps to manage complications, provides a hemodynamic back-up, and bridges to an emergency open heart surgery. The clinical outcomes of 27 patients who underwent prophylactic implantation of peripheral V-A ECMO (pV-A ECMO) during high-risk transcatheter aortic valve replacement (TAVR) cases are described. Methods: From June 2012 to October 2022, 590 consecutive patients underwent TAVR at our center. Of these, 27 patients (4.5%) underwent TAVR with pV-AECMO because they were deemed very high risk for periprocedural complications and formed the study population. Results: There were no pV-A ECMO, hemodynamic or TAVR implantation complications. Decannulation of the ECMO system was performed in 92.6% of cases at the end of the procedure in the hybrid-operating theatre. The mean duration of pV-A ECMO for procedure support was 51.4 ± 10.3 min. There were no ECMO-related vascular or bleeding complications. Conclusion: This study shows that the prophylactic placement of awake peripheral V-A ECMO provides excellent temporary cardio-circulatory and pulmonary support during very high-risk TAVR procedures.
- 20 January 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (3) , 859
Open AccessProphylactic Awake Peripheral V-A ECMO during TAVR
Introduction: TAVR remains a complex procedure that may result in serious intraprocedural complications. In many of these circumstances, venoarterial extracorporeal membrane oxygenation (V-A ECMO) helps to manage complications, provides a hemodynamic back-up, and bridges to an emergency open heart surgery. The clinical outcomes of 27 patients who underwent prophylactic implantation of peripheral V-A ECMO (pV-A ECMO) during high-risk transcatheter aortic valve replacement (TAVR) cases are described. Methods: From June 2012 to October 2022, 590 consecutive patients underwent TAVR at our center. Of these, 27 patients (4.5%) underwent TAVR with pV-AECMO because they were deemed very high risk for periprocedural complications and formed the study population. Results: There were no pV-A ECMO, hemodynamic or TAVR implantation complications. Decannulation of the ECMO system was performed in 92.6% of cases at the end of the procedure in the hybrid-operating theatre. The mean duration of pV-A ECMO for procedure support was 51.4 ± 10.3 min. There were no ECMO-related vascular or bleeding complications. Conclusion: This study shows that the prophylactic placement of awake peripheral V-A ECMO provides excellent temporary cardio-circulatory and pulmonary support during very high-risk TAVR procedures.